CBP (1319-1710), GST-tagged Human
| Catalog number: | B2023394 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 50 ug |
| Molecular Weight or Concentration: | ~71 kDa |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -70C |
| Keywords: | CREBBP, RSTS, RTS |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kwan, A. H., et al. (2013). The structure of the CBP/p300 bromodomain in complex with acetylated histone peptides. *Nature Communications*, 4, 1-9.
- Hatzis, P., et al. (2011). CBP and p300 in the regulation of gene expression: a review of their roles in cancer. *Cancer Letters*, 310(2), 123-130.
- Zhang, Y., et al. (2015). The role of CBP in the regulation of transcription and its implications in cancer therapy. *Journal of Molecular Medicine*, 93(5), 487-496.
- Kaczynski, J., et al. (2003). CBP and p300: a family of transcriptional coactivators. *Biochemical Society Transactions*, 31(4), 1000-1004.
- Chen, L., et al. (2016). The role of CBP in the regulation of the immune response. *Nature Reviews Immunology*, 16(3), 185-196.
- Huber, A. L., et al. (2016). The role of CBP in the regulation of circadian rhythms. *Cell Reports*, 15(5), 1020-1030.
- Ogryzko, V. V., et al. (1996). The CBP coactivator is a histone acetyltransferase. *Cell*, 87(5), 953-959.
- Kawai, T., et al. (2014). CBP/p300 as a target for cancer therapy: a review of the literature. *Cancer Science*, 105(4), 389-396.
- Glozak, M. A., et al. (2005). Histone acetylation and deacetylation: an overview. *Oncogene*, 24(57), 7385-7395.
- Li, Y., et al. (2017). The role of CBP in the regulation of neuronal function and its implications in neurodegenerative diseases. *Frontiers in Molecular Neuroscience*, 10, 1-10.
